Novel radiation therapy QA method: Monte Carlo simulation meets deep learning for fast, accurate epid transmission dose generation
Peer-Reviewed Publication
Updates every hour. Last Updated: 21-Jun-2026 22:16 ET (22-Jun-2026 02:16 GMT/UTC)
A research team led by Professor Fu Jin has developed an innovative method integrating Monte Carlo (MC) simulations with deep learning-based denoising technology to rapidly and accurately generate high-quality EPID transmission dose (TD) data. This breakthrough significantly enhances the efficiency of patient-specific quality assurance (PSQA), supporting the advancement of online adaptive radiation therapy (ART) in clinical practice.
Researchers at Brown University Health have identified a key molecular mechanism that may improve treatment for glioblastoma, one of the most aggressive forms of adult brain cancer. In a study published November 10 in Cell Reports, the team found that differences among cells within a single tumor play a major role in chemotherapy resistance and uncovered a small molecule, miR-181d, that helps regulate this variability. By stabilizing miR-181d levels, researchers were able to make tumor cells respond more uniformly to chemotherapy, potentially increasing its effectiveness. The discovery has already led to the development of a promising new gene-therapy–based approach aimed at improving outcomes for patients with glioblastoma.
Genetic ancestry plays a key role in determining the behavior of head and neck tumors and may help explain why African-American patients survive for half as long as their counterparts of European ancestry, according to a new review study led by researchers from the University of Maryland School of Medicine’s (UMSOM) Institute for Genome Sciences (IGS) and the University of Maryland Greenebaum Comprehensive Cancer Center (UMGCCC).
This review provides a comprehensive analysis of Growth Differentiation Factor 15 (GDF15) in prostate cancer (PCa), examining its complex influence on tumor metabolism, chemoresistance, and bone metastasis. GDF15 is identified as a critical driver of PCa progression and cancer cachexia, offering diagnostic potential as a biomarker, especially when combined with PSA. The review highlights promising ongoing clinical trials involving monoclonal antibodies (e.g., AV-380, NGM120, Visugromab) that target GDF15 signaling, marking it as a significant therapeutic opportunity for novel PCa therapie
Highlights
•
Marine ecosystems are rich in unique compounds such as alkaloids, peptides, polysaccharides, and terpenes with potent anticancer activities.
•
Marine-derived compounds exert their effects through multiple mechanisms, including apoptosis induction, cell cycle arrest, angiogenesis inhibition, and metastasis suppression.
•
Several marine compounds, like trabectedin and eribulin, have progressed to clinical use, showcasing the translational potential of marine-derived molecules in cancer therapy.
•
Despite promising results, challenges such as sustainable sourcing, structural complexity, and optimization for clinical application remain key hurdles in marine drug development.
Highlights
•
Genetic and epigenetic alterations, metabolic reprogramming, and survival mechanisms govern chemoresistance in cancer.
•
Cancer cells evade drug effects through metabolic reprogramming.
•
Resistance mechanisms are countered by tailored medicine and targeted medicines.
•
Combination regimens use a variety of strategies to overcome resistance
•
Novel treatment approaches to overcome resistance are guided by molecular understanding
A new machine learning tool has identified more than 250,000 cancer research papers that may have been produced by so-called “paper mills”.